Shares of PolyPid Ltd. dropped on Friday morning after the company said the Phase 3 study for its treatment D-PLEX(100) did not achieve its primary endpoint in reducing surgical-site infections for abdominal-surgery patients.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,